Copyright Reports & Markets. All rights reserved.

Global Eptacog Alfa (rFVIIa) Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Eptacog Alfa (rFVIIa) Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Prefilled Syringe
    • 1.3.3 Vial
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Eptacog Alfa (rFVIIa) Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Congenital Hemophilia
    • 1.4.3 Acquired Hemophilia
    • 1.4.4 Others
  • 1.5 Global Eptacog Alfa (rFVIIa) Market Size & Forecast
    • 1.5.1 Global Eptacog Alfa (rFVIIa) Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Eptacog Alfa (rFVIIa) Sales Quantity (2021-2032)
    • 1.5.3 Global Eptacog Alfa (rFVIIa) Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Novo Nordisk
    • 2.1.1 Novo Nordisk Details
    • 2.1.2 Novo Nordisk Major Business
    • 2.1.3 Novo Nordisk Eptacog Alfa (rFVIIa) Product and Services
    • 2.1.4 Novo Nordisk Eptacog Alfa (rFVIIa) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Novo Nordisk Recent Developments/Updates
  • 2.2 LFB SA
    • 2.2.1 LFB SA Details
    • 2.2.2 LFB SA Major Business
    • 2.2.3 LFB SA Eptacog Alfa (rFVIIa) Product and Services
    • 2.2.4 LFB SA Eptacog Alfa (rFVIIa) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 LFB SA Recent Developments/Updates
  • 2.3 GENERIUM
    • 2.3.1 GENERIUM Details
    • 2.3.2 GENERIUM Major Business
    • 2.3.3 GENERIUM Eptacog Alfa (rFVIIa) Product and Services
    • 2.3.4 GENERIUM Eptacog Alfa (rFVIIa) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 GENERIUM Recent Developments/Updates
  • 2.4 AryoGen Pharmed
    • 2.4.1 AryoGen Pharmed Details
    • 2.4.2 AryoGen Pharmed Major Business
    • 2.4.3 AryoGen Pharmed Eptacog Alfa (rFVIIa) Product and Services
    • 2.4.4 AryoGen Pharmed Eptacog Alfa (rFVIIa) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 AryoGen Pharmed Recent Developments/Updates
  • 2.5 Chia Tai Tianqing Pharmaceutical Group
    • 2.5.1 Chia Tai Tianqing Pharmaceutical Group Details
    • 2.5.2 Chia Tai Tianqing Pharmaceutical Group Major Business
    • 2.5.3 Chia Tai Tianqing Pharmaceutical Group Eptacog Alfa (rFVIIa) Product and Services
    • 2.5.4 Chia Tai Tianqing Pharmaceutical Group Eptacog Alfa (rFVIIa) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Chia Tai Tianqing Pharmaceutical Group Recent Developments/Updates

3 Competitive Environment: Eptacog Alfa (rFVIIa) by Manufacturer

  • 3.1 Global Eptacog Alfa (rFVIIa) Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Eptacog Alfa (rFVIIa) Revenue by Manufacturer (2021-2026)
  • 3.3 Global Eptacog Alfa (rFVIIa) Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Eptacog Alfa (rFVIIa) by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Eptacog Alfa (rFVIIa) Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Eptacog Alfa (rFVIIa) Manufacturer Market Share in 2025
  • 3.5 Eptacog Alfa (rFVIIa) Market: Overall Company Footprint Analysis
    • 3.5.1 Eptacog Alfa (rFVIIa) Market: Region Footprint
    • 3.5.2 Eptacog Alfa (rFVIIa) Market: Company Product Type Footprint
    • 3.5.3 Eptacog Alfa (rFVIIa) Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Eptacog Alfa (rFVIIa) Market Size by Region
    • 4.1.1 Global Eptacog Alfa (rFVIIa) Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Eptacog Alfa (rFVIIa) Consumption Value by Region (2021-2032)
    • 4.1.3 Global Eptacog Alfa (rFVIIa) Average Price by Region (2021-2032)
  • 4.2 North America Eptacog Alfa (rFVIIa) Consumption Value (2021-2032)
  • 4.3 Europe Eptacog Alfa (rFVIIa) Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Eptacog Alfa (rFVIIa) Consumption Value (2021-2032)
  • 4.5 South America Eptacog Alfa (rFVIIa) Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Eptacog Alfa (rFVIIa) Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Eptacog Alfa (rFVIIa) Sales Quantity by Type (2021-2032)
  • 5.2 Global Eptacog Alfa (rFVIIa) Consumption Value by Type (2021-2032)
  • 5.3 Global Eptacog Alfa (rFVIIa) Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Eptacog Alfa (rFVIIa) Sales Quantity by Application (2021-2032)
  • 6.2 Global Eptacog Alfa (rFVIIa) Consumption Value by Application (2021-2032)
  • 6.3 Global Eptacog Alfa (rFVIIa) Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Eptacog Alfa (rFVIIa) Sales Quantity by Type (2021-2032)
  • 7.2 North America Eptacog Alfa (rFVIIa) Sales Quantity by Application (2021-2032)
  • 7.3 North America Eptacog Alfa (rFVIIa) Market Size by Country
    • 7.3.1 North America Eptacog Alfa (rFVIIa) Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Eptacog Alfa (rFVIIa) Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Eptacog Alfa (rFVIIa) Sales Quantity by Type (2021-2032)
  • 8.2 Europe Eptacog Alfa (rFVIIa) Sales Quantity by Application (2021-2032)
  • 8.3 Europe Eptacog Alfa (rFVIIa) Market Size by Country
    • 8.3.1 Europe Eptacog Alfa (rFVIIa) Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Eptacog Alfa (rFVIIa) Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Eptacog Alfa (rFVIIa) Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Eptacog Alfa (rFVIIa) Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Eptacog Alfa (rFVIIa) Market Size by Region
    • 9.3.1 Asia-Pacific Eptacog Alfa (rFVIIa) Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Eptacog Alfa (rFVIIa) Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Eptacog Alfa (rFVIIa) Sales Quantity by Type (2021-2032)
  • 10.2 South America Eptacog Alfa (rFVIIa) Sales Quantity by Application (2021-2032)
  • 10.3 South America Eptacog Alfa (rFVIIa) Market Size by Country
    • 10.3.1 South America Eptacog Alfa (rFVIIa) Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Eptacog Alfa (rFVIIa) Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Eptacog Alfa (rFVIIa) Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Eptacog Alfa (rFVIIa) Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Eptacog Alfa (rFVIIa) Market Size by Country
    • 11.3.1 Middle East & Africa Eptacog Alfa (rFVIIa) Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Eptacog Alfa (rFVIIa) Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Eptacog Alfa (rFVIIa) Market Drivers
  • 12.2 Eptacog Alfa (rFVIIa) Market Restraints
  • 12.3 Eptacog Alfa (rFVIIa) Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Eptacog Alfa (rFVIIa) and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Eptacog Alfa (rFVIIa)
  • 13.3 Eptacog Alfa (rFVIIa) Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Eptacog Alfa (rFVIIa) Typical Distributors
  • 14.3 Eptacog Alfa (rFVIIa) Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Eptacog Alfa (rFVIIa) market size was valued at US$ 1557 million in 2025 and is forecast to a readjusted size of US$ 2043 million by 2032 with a CAGR of 4.0% during review period.
    In 2024, the global production of Eptacog Alfa (rFVIIa) will be 512 grams, with an average price range of around US$2,731 per mg.
    Eptacog Alfa (rFVIIa) is a recombinant activated coagulation factor used to control bleeding or prevent bleeding during surgery and invasive procedures. It is indicated for a variety of patient populations, including patients with congenital hemophilia who have inhibitors to coagulation factor VIII or IX (≥5 BU), patients with congenital hemophilia who are expected to have a strong immune response to coagulation factor VIII/IX replacement therapy, patients with acquired hemophilia, patients with congenital coagulation factor VII deficiency, and patients with thrombocytopenia accompanied by GP IIb/IIIa and/or HLA antibodies who are refractory or have an inadequate response to platelet transfusions.
    The global Eptacog Alfa (rFVIIa) market is dominated by a handful of key players: Novo Nordisk's original product, NovoSeven®, has become a global benchmark thanks to its widespread clinical application; LFB SA's Sevenfact®/Cevenfacta® offer differentiated alternatives for patients; GENERIUM's Coagil-VII®, launched in Russia, improves accessibility there and in the Commonwealth of Independent States (CIS); AryoGen Pharmed's AryoSeven® provides an economically viable solution in the Middle East; and Chia Tai Tianqing Pharmaceutical Group, China's first domestically produced rFVIIa product, received approval for marketing in 2025, filling a domestic market gap. With the joint development of these brands, rFVIIa is driving global hemostatic treatments from a "brand-name" model to a diversified supply, significantly improving patient accessibility and clinical outcomes.
    This report is a detailed and comprehensive analysis for global Eptacog Alfa (rFVIIa) market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Eptacog Alfa (rFVIIa) market size and forecasts, in consumption value ($ Million), sales quantity (kg), and average selling prices (USD/mg), 2021-2032
    Global Eptacog Alfa (rFVIIa) market size and forecasts by region and country, in consumption value ($ Million), sales quantity (kg), and average selling prices (USD/mg), 2021-2032
    Global Eptacog Alfa (rFVIIa) market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (kg), and average selling prices (USD/mg), 2021-2032
    Global Eptacog Alfa (rFVIIa) market shares of main players, shipments in revenue ($ Million), sales quantity (kg), and ASP (USD/mg), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Eptacog Alfa (rFVIIa)
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Eptacog Alfa (rFVIIa) market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, LFB SA, GENERIUM, AryoGen Pharmed, Chia Tai Tianqing Pharmaceutical Group, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Eptacog Alfa (rFVIIa) market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Prefilled Syringe
    Vial
    Market segment by Application
    Congenital Hemophilia
    Acquired Hemophilia
    Others
    Major players covered
    Novo Nordisk
    LFB SA
    GENERIUM
    AryoGen Pharmed
    Chia Tai Tianqing Pharmaceutical Group
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Eptacog Alfa (rFVIIa) product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Eptacog Alfa (rFVIIa), with price, sales quantity, revenue, and global market share of Eptacog Alfa (rFVIIa) from 2021 to 2026.
    Chapter 3, the Eptacog Alfa (rFVIIa) competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Eptacog Alfa (rFVIIa) breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Eptacog Alfa (rFVIIa) market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Eptacog Alfa (rFVIIa).
    Chapter 14 and 15, to describe Eptacog Alfa (rFVIIa) sales channel, distributors, customers, research findings and conclusion.

    Buy now